Skip to main content

Table 1 Adverse events

From: Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial

 

PC arm

AC arm (N = 354)

P value

(PC-post vs. AC)

Preoperative (N = 382)

Postoperative (N = 364)

All

Grade 3/4

All

Grade 3/4

All

Grade 3/4

All

Grade 3/4

Serious adverse events

8(2.1%)

3(0.8%)

12(3.3%)

6(1.6%)

18(5.1%)

11(3.1%)

1.000

1.000

Hematological

Anemia

251(65.7%)

30(7.9%)

191(52.5%)

25(6.9%)

201(56.8%)

23(6.5%)

0.246

0.842

Leukopenia

242(63.4%)

16(4.2%)

184(50.5%)

19(5.2%)

190(53.7%)

14(4.0%)

0.402

0.418

Neutropenia

209(54.7%)

75(19.6%)

173(47.5%)

54(14.8%)

162(45.8%)

67(18.9%)

0.636

0.143

Thrombocytopenia

292(76.4%)

40(10.5%)

250(68.7%)

32(8.8%)

243(68.6%)

28(7.9%)

0.991

0.670

Non-hematological

Anorexia

267(69.9%)

18(4.7%)

219(60.2%)

16(4.4%)

231(65.3%)

9(2.5%)

0.159

0.176

Diarrhea

180(47.1%)

12(3.1%)

156(42.9%)

9(2.5%)

130(36.7%)

11(3.1%)

0.093

0.605

Fatigue

288(75.4%)

20(5.2%)

247(67.9%)

12(3.3%)

245(69.2%)

14(4.0%)

0.697

0.637

Mucositis

108(28.3%)

2(0.5%)

89(24.5%)

1(0.3%)

105(29.7%)

3(0.8%)

0.116

0.303

Nausea

261(68.3%)

8(2.1%)

201(55.2%)

5(1.4%)

191(54.0%)

11(3.1%)

0.734

0.116

Neuropathy

187(49.0%)

14(3.7%)

157(43.1%)

15(4.1%)

144(40.7%)

9(2.5%)

0.505

0.239

Vomitting

121(31.7%)

6(1.6%)

94(25.8%)

8(2.2%)

104(29.4%)

8(2.3%)

0.287

0.955

  1. Chemotherapy population (patients who received at least one cycle of chemotherapy). Data are n (%). PC, perioperative chemotherapy; AC, adjuvant chemotherapy; PC-post, adverse events observed in postoperative chemotherapy in the PC group